RxDoctor Payments Data

Andrew Bromley, MD

Cardiovascular Disease · Miami, FLNPI 1699139683

Payments from drug & device makers

$59,678in general payments, 2019–2025

Across 98 payments — averaging $608.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$49K
  • Cvrx, Inc.$8K
  • Medtronic$749
  • Abbott$682
  • AstraZeneca$324
  • Boston Scientific$309
  • plus $1K from 17 others

What the payments were for

  • Consulting fees$2,40038%
  • Food & beverage$3,77260%
  • Education$1532%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$59,678 in reported general payments places this provider in the 85th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$187,995
Medicare patients
2,779
Services billed
4,666

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol216$239,906
EliquisApixaban167$208,096
EntrestoSacubitril/Valsartan103$144,290
JardianceEmpagliflozin90$124,449
Repatha SureclickEvolocumab114$91,517
XareltoRivaroxaban46$48,904
MounjaroTirzepatide28$37,640
OzempicSemaglutide33$36,277
MultaqDronedarone Hcl15$12,256
VascepaIcosapent Ethyl14$10,032
Ezetimibe304$8,221
DapagliflozinDapagliflozin Propanediol13$6,505
Rosuvastatin Calcium339$5,554
NexletolBempedoic Acid12$4,648
Telmisartan133$4,345

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$324$239,906216 claims
PfizerEliquis$43$208,096167 claims
NovartisEntresto$48,671$144,290103 claims
Boehringer IngelheimJardiance$28$124,44990 claims
Novo NordiskOzempic$123$36,27733 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →